All In Biotech

Drug Trial Radar · NCT04772105

Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular Edema

Phase Ib/IIa Study to Evaluate the Safety and Efficacy of Intravitreal Administration of Two Doses of BAT5906 Injection With Multiple Dosing Regimens in Patients With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Oct 16, 2020

Primary completion

Nov 6, 2023

Study completion Nov 6, 2023

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Feb 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, open, multiple-dose phase Ib/IIa clinical study evaluating the efficacy and safety of BAT5906 injection in patients with diabetic macular edema. BAT5906's phase I study on w-AMD shows that it is safe from 0.3-4.0 mg, and the higher dose (2.5 mg and 4 mg) may maintain the anti-VEGF effect for a longer time just like the same target drugs (such as brolucizumab and Abecip ) It has also been found in clinical studies that high doses can extend the dosing interval and reduce the dosing frequency. Therefore, in this study, two safe and effective doses were selected, and the optimal clinical effective dose and frequency of BAT5906 in DME were initially explored.

Conditions

  • Diabetic Macular Edema

Interventions

  • 2.5mg of BAT5906Drug

    Specification: 2.5mg of BAT5906

  • 4.0mg of BAT5906Drug

    Specification: 4.0mg of BAT5906

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1.1 Safety evaluation - Vital signs# the patient's body temperature;Time frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
  2. 1.2 Safety evaluation - Vital signs# heart rate/pulseTime frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
  3. 1.3 Safety evaluation - Vital signs# respiratory rateTime frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
  4. 1.4 Safety evaluation - Vital signs# blood pressureTime frame: Day-14~Day-1;Day0;Day28;Day56;Day84;Day112;Day140;Day168;Day196;Day224;Day252;Day280;Day308;Day336
  5. Number of subjects with clinically significant abnormal physical examination signs identified byprotocol-specified full physical examination (general appearance, skin, lungs, heart, abdomen,extremities, musculoskeletal system)Time frame: Day-14~Day-1;Day84;Day168;Day336
  6. Number of participants with clinically significant abnormal laboratory findingsTime frame: Day-14~Day-1;Day84;Day168;Day336
  7. Number of participants with clinically significant abnormal ECG findingsTime frame: Day-14~Day-1;Day84;Day168;Day336
  8. Anti-drug antibody (ADA);Time frame: Screening (within 24 hours prior to first dose), Day 7 (168h), Day 14 (336h), prior to the 3rd dose (within 24 hours), and prior to the 5th dose through end of study visit (as needed)
  9. ocular and non-ocular adverse events (AE) and serious adverse events (SAE)Time frame: Adverse events were collected from the time the patient signed the informed consent to the time 28 days after the last dication
  10. Efficacy evaluationTime frame: at Week 36
  11. Pharmacokinetic (PK) EvaluationTime frame: Once within 24 hours before administration.6 hours after administration, 24 hours after administration(once every 3 days) up to 672 hours after administration
  12. Peripheral Blood VEGF Assessment (VEGF)Time frame: Once within 24 hours before administration.24 hours after administration (once every 7 days) up to 672hours after administration
  13. Immunogenicity AssessmentTime frame: First administration: within 24 hours prior to administration.168 hours and 336 hours after administration,and the second until the last administration: within 24 hours before administration

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Hospital of China Academy of Chinese Medical Sciences

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • Henan Provincial Eye Hospital

    Henan, China

  • Jieyang People's Hospital

    Jieyang, China

  • The First Hospital of Jilin University

    Jilin City, China

  • The Affiliated Eye Hospital of Nanchang University

    Nanchang, China

  • Jiangsu Provincial Hospital of Traditional Chinese Medicine

    Nanjing, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • Affiliated Hospital of Qingdao University

    Qingdao, China

  • Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong

    Shantou, China

  • West China Hospital of Sichuan University

    Sichuan, China

  • Wenzhou Medical University Affiliated Optometry Hospital

    Wenzhou, China

  • The Second Xiangya Hospital of Central South University

    Xiangya, China

  • Xiangya Hospital Central South University

    Xiangya, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijiang, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.